2. UroToday Home
  3. Video Lectures

nmCRPC Videos

nmCRPC
Predictors of Survival, Healthcare Resource Utilization, and Healthcare Costs in Veterans with Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC) - Stephen Freedland
October 6, 2020
Details
nmCRPC
Significantly Longer Metastasis-Free Survival and Overall Survival in the ARAMIS Trial, Nonmetastatic Castration-Resistant Prostate Cancer - Christopher Wallis & Zachary Klaassen
September 30, 2020
Details
nmCRPC
ARAMIS Trial Demonstrates Significant Improvement in Overall Survival in nmCRPC - Neal Shore
June 29, 2020
Details
nmCRPC
The PROSPER Trial: Enzalutamide Demonstrates Significant Improvement in Overall Survival in Nonmetastatic Castration-Resistant Prostate Cancer - Cora Sternberg
June 15, 2020
Details
nmCRPC
Overall Survival Results of Phase III ARAMIS Study of Darolutamide Added to ADT for Non-metastatic Castration-Resistant Prostate Cancer (nmCRPC) - Karim Fizazi
June 9, 2020
Details
nmCRPC
ARAMIS Trial: Darolutamide Demonstrates Improved Overall Survival in Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC) - Fred Saad
May 28, 2020
Details
nmCRPC
Treatment Advances in Non-Metastatic Castration-Resistant Prostate Cancer - Evan Yu
May 18, 2020
Details
nmCRPC
Prolonging Overall Survival in Men with Non-metastatic Castration Resistant Prostate Cancer ARAMIS Trial - Neal Shore
April 13, 2020
Details
nmCRPC
Benefits of Early AR Targeting in Metastatic Hormone Sensitive Disease and nmCRPC - Karim Fizazi
April 3, 2019
Details
nmCRPC
Considerations for the Treatment of Non Metastatic Castration-Resistant Prostate Cancer - An Interview with Maha Hussain and Tia Higano
February 4, 2020
Details
nmCRPC
Long-term Follow-up of Non-metastatic (M0) Patients in the STAMPEDE Randomized Trial - Interview with Nicholas James
October 9, 2019
Details
nmCRPC
Darolutamide Treated Patients Maintained Quality of Life in ARAMIS Trial - Fred Saad
August 4, 2019
Details
nmCRPC
ARAMIS Trial in Prostate Cancer: Impact of Darolutamide on Pain and Quality of Life - Karim Fizazi
June 5, 2019
Details
nmCRPC
Darolutamide Demonstrates Efficacy and Safety in Men with nmCRPC - Neeraj Agarwal
February 26, 2019
Details
nmCRPC
ARAMIS - Efficacy and Safety of Darolutamide in nmCRPC - Karim Fizazi
February 21, 2019
Details
nmCRPC
Delaying Disease Progression in Early Nonmetastatic CRPC Treatment - Fred Saad
February 21, 2019
Details
nmCRPC
Abiraterone Acetate for nmCRPC, The Forgotten Dance Partner? - Zach Klaassen and Chris Wallis
December 12, 2018
Details
nmCRPC
IMAAGEN Trial: A Look into the Non-Metastatic Prostate Cancer Space - Charles Ryan
November 6, 2018
Details
nmCRPC
Comparison Between Surgery and Radiotherapy in the Treatment of Non-Metastatic Prostate Cancer- Christopher Wallis
November 2, 2018
Details
nmCRPC
Phase III ARAMIS Trial Darolutamide in Patients with Non-metastatic Castration-resistant Prostate Cancer Meets Primary Endpoint - Tom Keane
October 24, 2018
Details
nmCRPC
Combination Therapies and Quality of Life Data in Prostate Cancer - Fred Saad
October 11, 2018
Details
nmCRPC
nmCRPC Patient Population - Discussion with Charles Ryan and Alicia Morgans
October 8, 2018
Details
nmCRPC
The PROSPER Trial: Chemotherapy-Related Endpoints in Patients with nmCRPC - Neal Shore
August 14, 2018
Details
nmCRPC
AUA Castration-Resistant Prostate Cancer Guidelines - Interview with Michael Cookson
May 20, 2018
Details
nmCRPC
The Incredible Shrinking nmCRPC - Phillip Koo
May 14, 2018
Details
nmCRPC
The Implications of the SPARTAN Trial in the treatment of nmCRPC in Clinical Practice - Conversation with Eric Small
April 28, 2018
Details
nmCRPC
First presentation of SPARTAN - a phase 3 double-blind, randomized study of apalutamide (APA) versus placebo in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) - Eric Small
April 18, 2018
Details
nmCRPC
nmCRPC Outcomes in the Use of New Androgen Receptor Targeted Therapies - A Conversation with Charles Ryan and Alicia Morgans
April 3, 2018
Details
nmCRPC
nmCRPC - Early Treatment Leading to Favorable Outcomes - Fred Saad.
March 22, 2018
Details
nmCRPC
SPARTAN: A Study of Apalutamide in Men with M0 Castration-Resistant Prostate Cancer (M0 CRPC) - Alan Bryce
March 21, 2018
Details
nmCRPC
Meeting an Unmet Need in the Nonmetastatic Castration Resistant Prostate Cancer Patient Population - Maha Hussain
March 19, 2018
Details
nmCRPC
Changing the Landscape of nmCRPC - The SPARTAN Trial - Eric Small
March 6, 2018
Details